Catheter Precision Q1 revenue up 74% to $143K, net loss $4.0M; cash $450K

Catheter Precision, Inc.

Revenue $143K vs $82K YoY (+74%); net loss $4.0M including $1.2M non-cash charges.
Cash $450K at March 31; after quarter end secured $1.5M private placement from institutional investors.
Acquired Cardionomics assets via 82%-owned subsidiary Cardionomix, including CPNS system for ADHF.
Acquired PeriKard, LLC (pericardial access kit); first U.S. patent allowed for LockeT device.
Clinical data presented at HRS 2025: VIVO 94% accurate, LockeT safe/effective in 139-patient study.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.